Cellectis gives Bayer access to homologous recombination patents

Published: 13-Jan-2010
Research & Development Patient Experience

Cellectis, a French genome engineering company, and Bayer Healthcare have signed an agreement under which Bayer will have access to Cellectis" WO9011354 patent family covering homologous recombination aimed at introducing new features into the genome.


Cellectis, a French genome engineering company, and Bayer Healthcare have signed an agreement under which Bayer will have access to Cellectis" WO9011354 patent family covering homologous recombination aimed at introducing new features into the genome.

This global licence includes the use of the Institut Pasteur technology relating to homologous recombination to obtain and use certain transgenic animals in pharmaceutical research, in all countries, including Japan. Financial terms were not disclosed.

"Our licensing strategy is central to our business model and allows us to receive fair payment for the scientific and industrial advancements made possible by this technology. It continues to have a strong influence on the evolution of the company, as demonstrated by Cellectis" progress in the last ten years, and is an important component of our future growth strategy," said Cellectis" ceo Andre Choulika.

  • Companies:
  • Bayer
  • Cellectis
See more

You may also like

Research & Development

Recursion adds new chemical entity targeting fibrotic diseases to late discovery pipeline

Read more
Potential first-in-class molecule with novel target inlicensed from collaboration with Bayer

Trending Articles

  1. Sartorius Stedim Biotech supports bioprocess development with new Innovation Centre The Massachusetts, US-based Centre for Bioprocess Innovation is a collaborative space designed to develop and optimise biomanufacturing processes
  2. BioPharmaSpec expands its biopharma discovery and preclinical capabilities with three new facilities The contract research organisation (CRO) has expanded its European presence with three facilities, which are catered for biopharmaceutical drug discovery and preclinical characterisation
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    Parenteral preparations: formulation challenges Parenteral preparations are defined as solutions, suspensions, emulsions for injection or infusion, powders for injection or infusion, gels for injection and implants. They are sterile preparations that are administrated directly into the systemic circulation of humans or animals
  4. RCPE and InSilicoTrials to digitalise and accelerate the development of pharmaceutical manufacturing processes RCPE and InSilicoTrials have agreed to an exclusive partnership to commercialise the XPS simulation software. Specifically developed for pharmaceutical applications, XPS allows companies to assess their process configurations in unprecedented detail and explore the decision space without time- and labour-intensive experiments
  5. Transmission Raman Spectroscopy - access the webinar series today Offering significant advantages for bulk, quantitative and non-destructive analysis, Transmission Raman Spectroscopy is a preferred choice for applications where surface analysis is insufficient or prone to errors. Speakers from Agilent, Novartis Pharma, AstraZeneca, Bristol-Myers Squibb and AbbVie go deeper in this FREE webinar series

Upcoming event

CPhI India

26–28 November 2024 | Online Conference & Networking | Delhi, India See all

You may also like

Research & Development

Recursion adds new chemical entity targeting fibrotic diseases to late discovery pipeline

Potential first-in-class molecule with novel target inlicensed from collaboration with Bayer
Regulatory

Pistoia Alliance announces data management toolkit

Roche, AstraZeneca and Bayer supports FAIR Implementation project to improve data management and better AI and machine learning for the "Lab of the Future"
Design & Build

Bayer chooses Fluor and GE Healthcare for new cell culture technology centre

Company will invest US$150 million in new California facility expected to be ready for clinical production in late 2021
Media

TissUse establishes a multi-organ model for risk assessment with Bayer

The biotechnology company has signed a collaboration agreement with the pharmaceutical and life sciences company to develop a liver-endocrine tissue assay
Drug Delivery

Bayer and DelSiTech link up to develop new ophthalmology drug delivery technology

Agreement highlights the potential of biodegradable silica material in demanding drug delivery applications
Research & Development

Casebia Therapeutics establishes operations in Cambridge (MA, USA)

Hiring is underway and efforts have begun on haematology and ophthalmology programmes
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

ADCs: a more effective, less harmful, targeted approach

Antibody-drug conjugates could hold the key to delivering highly potent anticancer drugs more accurately to the tumour site with less damage to healthy cells
Subscribe now